How Much Did FirstString Research Raise?
Funding & Key Investors

FirstString Research has solidified its position in the clinical-stage biotechnology sector, securing a total capital infusion of $10.2M. This financial trajectory, marked by a recent strategic investment of $203K, underscores the market confidence in the company's proprietary peptide mimetic technology. By leveraging significant backing, the firm continues to advance its core therapeutic pipeline through rigorous clinical validation, positioning itself as a key player in the multi-billion dollar wound care market.

The company's growth narrative is defined by a series of strategic financing rounds, beginning with early-stage capital and evolving into major enterprise-level funding. This progression reflects the successful transition from foundational research at the Medical University of South Carolina to advanced Phase 3 clinical development, demonstrating a robust commitment to addressing unmet medical needs in diabetic foot ulcers and venous leg ulcers.